Foundayo, Eli Lilly's once-daily weight-loss tablet, was approved in the United States on 1 April 2026. It has no licence in the United Kingdom. This page sets out exactly where the UK process stands, what has to happen before anyone here can be prescribed it, and — because the honest answer involves uncertainty — which dates are confirmed and which are educated guesses.
There is no confirmed Foundayo UK release date. Lilly has submitted orforglipron to regulators in more than 40 countries, including the UK. Industry commentary expects an MHRA decision somewhere between late 2026 and early 2027, with private prescriptions likely first and NHS access — if NICE recommends it — realistically 2027 or later. Until the MHRA grants a licence, nobody in the UK can legally sell or prescribe Foundayo, and any site claiming otherwise is selling something unlawful and unsafe.
Where things stand: approved in the US, submitted in the UK
The confirmed facts are straightforward. The US Food and Drug Administration approved Foundayo (generic name orforglipron) on 1 April 2026, for adults with obesity — or some adults with overweight who also have weight-related medical problems — to reduce excess body weight and keep it off, alongside a reduced-calorie diet and increased physical activity. The approval moved unusually quickly: it went through the FDA's National Priority Voucher pilot and cleared roughly 50 days after filing.
Interest in the drug is not hard to explain. In its main phase 3 trial, published in the New England Journal of Medicine, the highest study dose produced an average 12.4% body-weight reduction over 72 weeks, against 0.9% with placebo, and 39.6% of participants on that dose lost at least 15% of their body weight — results delivered by a once-daily tablet that can be taken at any time of day, with no food or water restrictions. You can read more about how the drug came to exist on our development and history page.
For the UK, the position is different. Lilly has said it has submitted orforglipron for approval in more than 40 countries, including the UK, and plans to launch in each market shortly after clearance. As of mid-2026, the MHRA — the Medicines and Healthcare products Regulatory Agency, the UK's medicines regulator — has not approved it. That single fact governs everything else on this page: until a licence exists, Foundayo cannot legally be prescribed, sold or supplied anywhere in the UK, privately or on the NHS.
What the MHRA review involves
The MHRA assesses whether a medicine's quality, safety and efficacy justify a UK licence (formally, a marketing authorisation). Analysts expect Lilly's UK application to go through the International Recognition Procedure — a route that lets the MHRA lean on the completed FDA review rather than repeating every assessment from scratch. A standard MHRA review runs on the order of 150 to 210 days. It is worth being plain about the strength of this information: the submission itself is well reported, but the exact route and internal timings are analyst expectation, not anything the MHRA publishes case by case.
Put those pieces together and you get the consensus estimate that circulates in UK pharmacy and industry commentary: a possible MHRA licence between late 2026 and early 2027. Treat that as a forecast. Neither Lilly nor the MHRA has committed to a date, regulatory reviews can raise questions that add months, and this page will be updated when a decision is announced rather than speculated about.
A realistic UK timeline, stage by stage
Two separate gates stand between a new medicine and a patient in the UK. The first is the MHRA licence. The second — for NHS availability — is a NICE appraisal. They run in sequence, which is why "approved" and "available on the NHS" can sit a year or more apart.
| Stage | Status | Timing |
|---|---|---|
| US FDA approval | Confirmed | 1 April 2026 |
| UK MHRA submission | Submitted / under review | Part of Lilly's 40-plus-country filing programme |
| MHRA licence decision | Expectation only | Late 2026 to early 2027 (unconfirmed) |
| Private prescriptions in the UK | Expectation only | Shortly after any MHRA licence |
| NICE appraisal for NHS use | Process known; timing projected | Roughly 6–9 months after licensing |
| NHS availability (if recommended) | Expectation only | Realistically 2027 or later, likely restricted to defined patient groups |
Private availability would come first
Private prescribing does not have to wait for the NICE process, because NICE decides NHS funding rather than whether a licensed medicine may be prescribed at all. UK pharmacy commentary therefore expects private prescriptions to become possible fairly soon after any MHRA licence — which, if the late-2026-to-early-2027 licence window proves right, would mean private availability somewhere in late 2026 or during 2027. It is worth being clear that this expectation rests on limited sourcing: it is a projection from industry commentary, not a commitment from Lilly, the MHRA or anyone else. Even then, Foundayo would be a prescription-only medicine — a prescriber would need to assess whether it is clinically appropriate for you, and would be free to conclude it is not. No UK price has been announced. For context only: in the US, the manufacturer's self-pay channel prices the tablet from about $149 per month at the lowest strength up to about $349 at the highest. That tells you what one company charges in one very different market — UK private pricing, when it exists, will be set separately.
NHS access runs through NICE
For NHS prescribing, a licence is only step one. NICE — the National Institute for Health and Care Excellence — must then appraise whether the drug is clinically effective and cost-effective for NHS use. That appraisal typically takes around six to nine months after licensing, and if NICE says yes, NHS England normally has to make the medicine available within about three months of final guidance. A realistic reading is therefore an NHS funding verdict in 2027 or later — and, going by how Mounjaro and Wegovy were handled, any recommendation would likely be restricted to defined groups, such as people above certain BMI thresholds with weight-related conditions, rather than open access. If you are hoping to get Foundayo on the NHS soon after a licence appears, it is worth calibrating expectations now: the gap between licensing and routine NHS prescribing is usually measured in months to years, not weeks.
Nobody can legally sell you Foundayo in the UK today
This is the part of the page that matters most right now. Because there is no MHRA licence, any website, social-media seller or clinic claiming to supply "Foundayo" or "orforglipron" to UK customers in July 2026 is acting unlawfully — and whatever arrives in the post will not be a genuine, quality-assured medicine. There is no legal grey area here, and no legitimate early-access retail channel.
If you are trying to judge whether an online offer could possibly be legitimate, the following signs settle the question:
- Selling it at all. The strongest red flag is the simplest: the product has no UK licence, so any UK offer of it is illegitimate by definition. You do not need to examine the website's polish.
- No prescriber involvement. Genuine UK supply of prescription-only medicines always involves a prescription from a qualified prescriber. "No consultation needed" means unlawful supply.
- Pressure tactics. Countdown timers, "pre-order before UK approval", crypto or bank-transfer payment, and prices that seem surprisingly good should all be read the same way: no legitimate supply of this medicine exists in the UK, so an offer dressed up with urgency is an offer to avoid.
The practical consequence is worth spelling out. A product bought outside the legal supply chain has never passed through the quality-assurance system that a licence exists to enforce, so there is no reliable way to know what tablets sold that way actually contain. If you come across a site selling "Foundayo" to UK buyers, you can report it to the MHRA, which investigates illegal medicine sales. And if you have taken any weight-loss medicine — licensed or not — and experienced side effects, report them through the MHRA Yellow Card scheme and speak to your GP or pharmacist. Our side-effects page explains what was actually reported in the clinical trials, which is a useful baseline for that conversation.
What UK readers can usefully do in the meantime
Waiting for a specific unlicensed drug is rarely a good health plan. If weight is affecting your health now, the NHS obesity pages set out the options that already exist, from structured support to the weight-loss medicines that are currently licensed in the UK — and your GP can tell you which, if any, are appropriate for you. If Foundayo does arrive, it will be one option among several for a prescriber to weigh, not an automatic upgrade.
If you want to understand the drug itself while the regulatory process runs, the most concrete thing about it is how it is dosed: six tablet strengths, started low and increased slowly to limit stomach-related side effects. Our dosage and titration guide walks through the approved US schedule in detail.
Frequently asked questions
Can I buy Foundayo in the UK right now?
No. With no MHRA licence, Foundayo cannot legally be prescribed, sold or supplied in the UK — privately or on the NHS. Any seller claiming otherwise is operating illegally, and its products are, at best, not the genuine medicine.
When is the Foundayo UK release date?
There isn't one yet. Lilly has submitted the drug to the MHRA as part of a 40-plus-country filing programme; industry expectation is a possible licence between late 2026 and early 2027, with private availability likely to follow first. That window is a forecast, not a commitment from Lilly or the MHRA.
Will Foundayo be available on the NHS?
Only if the MHRA licenses it and NICE then recommends it as clinically and cost-effective. NICE appraisals typically take around six to nine months after licensing, so an NHS verdict realistically lands in 2027 or later — and, as with Mounjaro and Wegovy, access would likely be restricted to defined patient groups.
How much will Foundayo cost in the UK?
No UK price exists. The only published reference is US manufacturer self-pay pricing, which starts around $149 per month — context, not a prediction. UK private prices will be set separately once a licence exists.
References
- Eli Lilly and Company. FDA approves Lilly's Foundayo (orforglipron), the only GLP-1 pill for weight loss. Investor news release, April 2026. investor.lilly.com
- US Food and Drug Administration. NDA 220934 approval letter, 1 April 2026. accessdata.fda.gov
- Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist — ATTAIN-1 phase 3 results. New England Journal of Medicine. nejm.org
- Eli Lilly and Company. Foundayo coverage and savings (US self-pay pricing). foundayo.lilly.com
- Medicines and Healthcare products Regulatory Agency (MHRA) — the UK medicines regulator. gov.uk
- National Institute for Health and Care Excellence (NICE) — technology appraisals determine NHS funding. nice.org.uk
- NHS. Obesity — overview and treatment options. nhs.uk
- MHRA Yellow Card scheme — report suspected side effects from any medicine. yellowcard.mhra.gov.uk